RxDoctor Payments Data

Mohammed Said Malas, MD

Nephrology · Clermont, FLNPI 1215249966

Payments from drug & device makers

$3,096in general payments, 2019–2025

Across 137 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$655
  • Otsuka America Pharmaceutical, Inc.$419
  • Amgen$319
  • Calliditas Therapeutics US Inc.$224
  • Novartis$194
  • Baxter Healthcare$167
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,88493%
  • Education$2127%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,096 in reported general payments places this provider in the 60th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$121,017
Medicare patients
301
Services billed
911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide31$78,489
LokelmaSodium Zirconium Cyclosilicate19$26,182
VeltassaPatiromer Calcium Sorbitex16$16,647
Sevelamer Carbonate34$9,391
SpsSodium Polystyrene Sulfon/Sorb13$7,649
Potassium Citrate ErPotassium Citrate45$6,105
Torsemide64$1,869
Potassium Chloride60$1,795
Metolazone44$1,603
Nifedipine ErNifedipine24$1,160
Furosemide138$986
Losartan Potassium96$916
Hydralazine Hcl28$821
Doxazosin Mesylate38$641
Cinacalcet Hcl14$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$63$78,48931 claims
AstraZenecaLokelma$655$26,18219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 756 nephrology providers in Florida.

Other nephrology in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →